about
Structured telephone support or telemonitoring programs for patients with chronic heart failureA genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathyIs aspirin useful in primary prevention?Targeting myocardial substrate metabolism in heart failure: potential for new therapiesCardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicityThe Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristicsClinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failureThe Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failureWhat is the optimal medical management of ischemic heart failure?Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?No reduction in cardiovascular risk with NSAIDs-including aspirin?The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatmentChronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?Effects of applying a standardised management algorithm for moderate to severe renal dysfunction in patients with chronic stable heart failureShould β-blockers be used in patients with heart failure and atrial fibrillation?Prevalence of scarred and dysfunctional myocardium in patients with heart failure of ischaemic origin: a cardiovascular magnetic resonance studyTelemonitoring or structured telephone support programmes for patients with chronic heart failure: systematic review and meta-analysis.The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study.2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm AssociAngiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.Modification of atherosclerosis by agents that do not lower cholesterolACE inhibitors: current understanding and future directions.ACE inhibitors for heart failure: a question of doseHeart failure due to ischaemic heart disease: epidemiology, pathophysiology and progression.Systematic review of the management of atrial fibrillation in patients with heart failure.The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.Endothelin antagonists for chronic heart failure: do they have a role?Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve?Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)Design and Usage of the HeartCycle Education and Coaching Program for Patients With Heart FailurePrevention of and medical therapy for atrial arrhythmias in heart failure.Micronutrient deficiencies an unmet need in heart failure.Beta-blockers for heart failure: why, which, when, and where.The heart failure revascularisation trial (HEART): rationale, design and methodology.Update of clinical trials from the American College of Cardiology 2003. EPHESUS, SPORTIF-III, ASCOT, COMPANION, UK-PACE and T-wave alternans.Reliability of reporting left ventricular systolic function by echocardiography: a systematic review of 3 methods.The utility of a comprehensive cardiac magnetic resonance examination for the evaluation of patients with heart failureExercise capacity and cardiac function assessed by tissue Doppler imaging in chronic heart failure.Clinical trials update from the American Heart Association meeting: Omega-3 fatty acids and arrhythmia risk in patients with an implantable defibrillator, ACTIV in CHF, VALIANT, the Hanover autologous bone marrow transplantation study, SPORTIF V, OR
P50
Q24242621-7B23D474-5A65-496D-BE66-91926A143ACEQ24601469-E3AAA65E-9C59-4B0C-AD24-3F98A49DC491Q27001149-E71CBEA4-F121-4DA3-8F3C-25867CA6B16BQ27694733-28135FE7-34C3-4F64-BF0F-E9528FE881E8Q28166985-68DCB85E-33D5-4BCD-A899-0CCED0090FEFQ28168358-E2D338E1-4D1A-4B6B-B417-C205F1DF098BQ28168872-8ADD0916-7755-4FA1-ACCE-51D85EF2F4D3Q28169100-4944A881-F99D-414E-8859-6A9FE55BA6F6Q28177157-9E765FBB-803A-4514-807D-D8459CC16AEAQ28187802-FCF50D77-8BE3-4D11-9925-2CB69FE40B19Q28192226-ED824284-8D19-40D4-A10C-86250FC817C1Q28195357-256B8598-84FC-42C3-BB2C-716446E04201Q28196889-66E39E45-7E8E-428E-B0B0-F0062279B74BQ28212766-9ED955DB-A7C6-403C-9AC1-D1E31CC1326AQ28267603-19CE60FB-E865-4EBB-A1AF-50DA3048D41EQ30473748-6636DE37-CE44-470C-BE4D-F25C6D4B405AQ30479428-940AE8E7-E501-4473-A11E-FF60F2464945Q30982366-D12D1A6F-695A-4F93-BEE2-EDC2A81F9DABQ33162947-3593A2C3-C13E-466E-8084-395524794444Q33172373-CDA266F7-4376-4F9A-8739-A603987E0457Q33613230-2195FA11-3F43-4815-B814-87DEC81259D7Q33614264-D12934F5-F8BD-4E2E-8A8B-F86B4CE33EE6Q33614305-C1E7CCE0-4AB9-43A3-8E69-3F1D88772B25Q33708706-F7FE926C-E0D0-431F-863E-A276D0073524Q33872056-55966754-607E-4A65-8794-4DA132A95153Q34209536-4C510F6F-F018-453C-BE6A-F5C2AE584010Q34264689-A7A2E3D4-013C-47F0-A495-BA77B15855ACQ34363699-AD6F767D-DCA2-4872-A1E3-538BD1EFFD6BQ34660839-3A4E583C-61F5-45B0-8D29-5A9F34AF9D7BQ34697156-13520C7B-0B10-4317-B638-A95049E48AC4Q34766692-1F7702E2-18F3-40A3-9DAE-4442D1A86E1DQ34821575-B68C1B02-FCD5-4BC8-AA79-B196BDFFC3E2Q35009114-71843D91-3745-4692-9C86-2B459B90DD3DQ35106468-FA6DF734-2D09-4E41-8333-137F96F8DB9CQ35150706-62EACA9A-EEC7-40C2-A456-FDD37FE8FC64Q35150715-19402587-418D-44CE-BB54-A0B334BB6671Q35208798-43389512-B530-4D80-8FDE-0032ADB9E692Q35582897-C8F9DFEE-2A5F-46EF-BD26-9FB481BF1869Q35582991-5883692D-24BD-4FF1-ADB8-3382F36D5170Q35687674-C432FD1C-7832-4BED-8FF0-A0DB630A21BF
P50
description
cardioloog
@nl
hulumtues
@sq
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
John Cleland
@en
John Cleland
@es
John Cleland
@nl
John Cleland
@sl
John G. F. Cleland
@de
type
label
John Cleland
@en
John Cleland
@es
John Cleland
@nl
John Cleland
@sl
John G. F. Cleland
@de
prefLabel
John Cleland
@en
John Cleland
@es
John Cleland
@nl
John Cleland
@sl
John G. F. Cleland
@de
P108
P227
P1153
7202164137
P21
P214
8165147907516879210004
P227
1118645952
P2456
P31
P496
0000-0002-1471-7016